Teleflex LLC Powered Bone Marrow Systems

SUNY Upstate Medical University is seeking to procure Teleflex LLC Powered Bone Marrow Systems and Related Products through a procurement process authorized under section 163 (3) (vi) of New York State regulations. The procurement will leverage a contract awarded by Premier, allowing for purchase without a formal competitive process when justified by pricing. Potential vendors must demonstrate clinical equivalency to the specified Teleflex systems, which requires providing free supporting clinical documentation and equipment for examination and trial. Vendors interested in participating must contact Taylor Butchko at HayesTa@upstate.edu to discuss procurement details. The procurement is specifically located in Onondaga County and is subject to NYS Finance Law 139 j&k (Lobbying Law), which strictly limits vendor communication to the designated contact person. The procurement window opens on March 14, 2025, with proposals due by April 4, 2025, at 8:00 AM, and the contract term will extend through the expiration of the Premier Contract PP-NS-2025. Vendors must be authorized to sell Teleflex LLC Powered Bone Marrow Systems or an approved equivalent.

The procurement opportunity does not include a Service-Disabled Veteran-Owned business set-aside, and no business entities have been awarded an identical or substantially similar contract within the past five years. Successful contractors will be required to submit valid and current NYS Workman's Compensation and Disability Forms. The procurement process emphasizes strict compliance with communication protocols, with potential consequences ranging from contract disqualification to debarment from sales to New York State agencies for vendors who do not adhere to the specified guidelines. While specific budget ranges are not explicitly stated, the procurement is structured to secure medical systems through an existing consortium contract, suggesting a potentially significant investment in specialized medical equipment. The emphasis on clinical performance and equivalency suggests that qualitative factors will play a crucial role in vendor selection, beyond simple price considerations.